FDA Drug vs Biologic Definition: Where Peptides Fall | FormBlends

Trust Signals

Key Takeaways

What Is the FDA Drug vs Biologic Definition for Peptides? (Direct Answer)

Table of Contents

1. What the statutes actually say: the two definitions side by side
2. Where the 40-amino-acid rule comes from and what it does not resolve
3. Evidence ledger: how solid is each classification claim?
4. Real examples: approved peptides mapped to their pathway
5. What most pages get wrong about peptide classification
6. Why the classification matters operationally (compounding, generics, exclusivity)
7. Head-to-head: drug pathway vs biologic pathway for a peptide sponsor
8. Chemistry behind the rule: why complexity, not size alone, drives the logic
9. Label and COA literacy: how to identify which category a product claims
10. FAQ
11. Sources
12. Footer Disclaimers

What Do the Statutes Actually Say? The Two Definitions Side by Side

The Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(g)) defines a drug as any article intended to diagnose, cure, mitigate, treat, or prevent disease, or intended to affect the structure or function of the body. This definition is intentionally broad and captures peptides, small molecules, botanical extracts, and many other substance classes.

The Public Health Service Act (42 U.S.C. 262(i)) defines a biological product as a virus, therapeutic serum, toxin, antitoxin, vaccine, blood or blood component, allergenic product, protein, or analogous product applicable to the prevention, treatment, or cure of a disease or condition. The BPCIA (Public Law 111-148, Section 7002) added "protein" to this list and defined it as an amino acid polymer with a specific defined sequence, greater than a certain size threshold, expressed through extraction, chemical synthesis, or recombinant technology. That size threshold, codified in FDA guidance and agency practice, is 40 amino acids.

The definitions overlap. A 31-amino-acid peptide like semaglutide technically affects body structure/function (drug definition) but falls below the protein threshold (not a biologic). A 51-amino-acid molecule like insulin (counting both chains) crosses the protein threshold and, after March 23, 2020, is a biologic. Congress and the FDA chose a bright-line rule precisely because the biology does not offer one.

Where Does the 40-Amino-Acid Rule Come From and What Does It Not Resolve?

The 40-amino-acid threshold was not chosen for mechanistic reasons. It was a regulatory compromise intended to distinguish molecules that can be fully characterized by chemical synthesis (small peptides) from proteins whose three-dimensional structure, glycosylation, and manufacturing-process dependence make full characterization difficult. The FDA articulated this logic in its 2018 Guidance for Industry, "Considerations for the Design, Development, and Analytical Procedures for Peptide Drug Products."

What the rule does not resolve:

• Multi-chain peptides: Insulin has a 21-amino-acid A chain and a 30-amino-acid B chain. Neither chain alone exceeds 40 residues. The FDA treats the assembled dimer as the relevant molecule, which crosses the threshold. The rule does not specify how to count across disulfide-linked chains, and the FDA resolves ambiguous cases through product-specific guidance.
• Chemically modified peptides: Semaglutide has a fatty acid chain attached to a lysine residue at position 26. That modification does not add amino acids. The molecule remains 31 amino acids, remains a drug, and the modification is treated as a non-amino-acid excipient for counting purposes. Liraglutide is similarly 26 amino acids with a fatty acid tag, regulated as a drug (NDA 022341).
• Cyclic peptides and non-standard amino acids: The FDA has not published a bright-line rule for every cyclic or D-amino-acid containing peptide. These are resolved case by case.
• The "analogous product" clause: Even below 40 amino acids, the FDA retains discretion to classify a product as a biologic if it is an "analogous product" derived from a living organism. This clause is rarely invoked for synthetic peptides but has never been formally retired.

Evidence Ledger: How Solid Is Each Classification Claim?

Real Examples: Approved Peptides Mapped to Their Pathway

Note on TB-500: Thymosin beta-4 has 43 amino acids, placing it above the 40-AA threshold. If it were to seek FDA approval, the sponsor would almost certainly file a BLA, not an NDA. That also means it cannot be lawfully compounded under the FDCA compounding exemptions. This is a point almost no other source makes clearly.

What Most Pages Get Wrong About Peptide Classification

Most medspa and research vendor pages treat "peptide" and "drug" as mutually exclusive, or conflate "not FDA approved" with "not regulated." Both errors mislead readers in ways that carry real legal and safety consequences.

Error 1: "Peptides are biologics by definition." False. The majority of research-used and clinically approved peptides, including semaglutide, teriparatide, and oxytocin, are drugs under the FDCA, not biologics. The 40-amino-acid line is the operative statutory distinction, and most short synthetic peptides fall well below it.

Error 2: "Research-use-only peptides are unregulated." False. The FDA does not have a formal "research chemical" exemption for peptides. An unapproved peptide sold with implicit or explicit intent for human use is an unapproved new drug subject to enforcement under 21 U.S.C. 331. The RUO label limits liability only when the product is genuinely used in non-clinical research.

Error 3: "Any compounding pharmacy can make any peptide." False for two reasons. First, peptides above 40 amino acids (biologics) cannot be compounded under FDCA exemptions. Second, the FDA has designated certain approved drug-pathway peptides, including semaglutide, as no longer on the shortage list after shortage periods end, which removes the shortage-based compounding pathway for 503A and 503B pharmacies.

Error 4: "Generic peptides are coming soon." This conflates the drug and biologic pathways. A peptide drug (below 40 AA) can have a generic approved via ANDA once patents expire. A peptide biologic (40+ AA) faces the biosimilar pathway, which requires demonstrating no clinically meaningful difference from the reference product, a substantially higher evidentiary burden than ANDA bioequivalence.

Why the Classification Matters Operationally: Compounding, Generics, and Exclusivity

Compounding access. FDCA Sections 503A and 503B create limited exemptions allowing licensed pharmacies and outsourcing facilities to compound drug products without individual NDA approval. These exemptions are limited to "drug products" as defined in the FDCA. Biological products under the PHS Act are outside the scope of these exemptions. The practical consequence: a 503A pharmacy can compound teriparatide (34 AA, drug) but cannot compound a biologic peptide. The FDA's 2022 enforcement letters to compounders producing semaglutide during shortage were issued under the drug pathway, because semaglutide is a drug, not a biologic. That distinction protected the compounders' legal argument during the shortage period.

Exclusivity periods. The Hatch-Waxman Act grants 5 years of new chemical entity (NCE) exclusivity to the first approval of a small molecule or small peptide with no previously approved active moiety. The BPCIA grants 12 years of reference product exclusivity to an approved biologic. For a peptide sponsor, achieving biologic classification can more than double the exclusivity window, making classification a strategic decision that patent counsel and regulatory affairs teams negotiate with the FDA early in development.

Generic and biosimilar entry. Once NCE exclusivity expires for a drug-pathway peptide, an ANDA filer must show pharmaceutical equivalence (same active ingredient, dosage form, route, and strength) and bioequivalence (generally shown by pharmacokinetic studies in healthy volunteers). For a biosimilar, the applicant must show no clinically meaningful differences from the reference product across analytical studies, animal studies where relevant, and at least one clinical pharmacology study. The biosimilar standard is more expensive and more uncertain. This is why biosimilar entry typically takes longer and results in smaller initial market share than generic entry after small-molecule exclusivity expiration.

Head-to-Head: Drug Pathway vs Biologic Pathway for a Peptide Sponsor

Chemistry Behind the Rule: Why Complexity, Not Size Alone, Drives the Logic

The 40-amino-acid threshold is a proxy for a more fundamental concern: characterizability. A chemist with a mass spectrometer can fully define the primary structure of a 15-amino-acid peptide. A 150-amino-acid protein folds in three dimensions, forms disulfide bonds, acquires post-translational modifications (glycosylation, phosphorylation, acetylation), and may exist as oligomers. Two batches synthesized identically at the amino-acid sequence level may differ in glycan composition, folding, and aggregation, producing different immunogenicity and efficacy profiles. No single analytical technique captures all of that variation.

This is why the FDA's biologics regulatory framework demands that the manufacturing process itself be validated as part of approval. The phrase "the process is the product" describes this reality. For a 31-amino-acid peptide like semaglutide, a sponsor can provide a complete chemical characterization (full sequence confirmed by tandem mass spectrometry, stereochemistry confirmed by chiral HPLC, fatty acid modification confirmed by NMR) and demonstrate that any manufacturer producing an identical molecule would produce identical effects. That full characterizability is what earns the drug designation and allows a relatively straightforward generic pathway later.

The honest limit of this logic: some peptides below 40 amino acids are not fully synthetic and are derived from biological sources (naturally occurring peptide hormones extracted from animal tissue, for instance). The "analogous product" clause in the biologic definition covers these cases. So the 40-AA rule is a bright line for fully synthetic peptides; it is not absolute for biologically derived ones.

Label and COA Literacy: How to Identify Which Category a Product Claims

If you are evaluating a peptide product, a certificate of analysis (COA), product label, or supplier documentation should allow you to determine the following:

• Amino acid count: Confirmed by sequence data or mass spectrometry. If the COA lacks sequence confirmation and provides only a purity percentage by HPLC, you cannot confirm the molecule is what is claimed. A reputable supplier provides both molecular weight (confirmed by LC-MS) and purity (by HPLC). Mass discrepancies of even a few daltons indicate truncation, deletion, or impurity.
• Regulatory status claim: Labels should state "For Research Use Only. Not for human use." This does not mean unregulated; it defines the intended use. If a supplier's website includes dosing guidance for humans alongside an RUO label, that is a red flag for regulatory non-compliance.
• Compounding pharmacy context: A compounding pharmacy preparing a peptide under 503A should be able to identify the FDA-approved drug form it is compounding from, or the bulk drug substance it is using from the FDA's 503A Bulks List. If a compounder cannot cite either, the product's legal status is uncertain.
• NDA or BLA number: For any claimed approved peptide, verify the NDA or BLA number at FDA Drugs@FDA (drugs.fda.gov). Look up the active ingredient, confirm the applicant, and verify the approval date. Do not accept a brand name alone as proof of approval for the specific formulation being sold.
• Stability indicators: A degraded peptide may show a lower purity percentage on HPLC, the appearance of new peaks at shorter retention times (degradation products), or a reduced main peak area. Peptides should be stored per the COA specification, typically frozen for long-term storage, and the COA should include a retest date, not just a manufacture date.

FAQ

What is the FDA's definition of a drug vs a biologic?

A drug under 21 U.S.C. 321(g) is any article intended to diagnose, cure, treat, prevent, or mitigate disease, or to affect the structure or function of the body. A biologic under 42 U.S.C. 262 is a virus, serum, toxin, antitoxin, vaccine, blood component, allergenic product, protein, or analogous product applicable to disease prevention or treatment. The definitions overlap considerably; the regulatory pathway, not the molecular category alone, determines which applies.

What is the 40-amino-acid rule for peptides at the FDA?

The BPCIA (2009), as implemented, treats proteins of 40 or more amino acids as biologics regulated under Section 351 of the PHS Act. Peptides with fewer than 40 amino acids are generally regulated as drugs under Section 505 of the FDCA, unless they meet another biologic criterion such as being derived from a living organism.

Are all peptides classified as biologics?

No. Most synthetic peptides used in research and compounding, such as BPC-157, and most approved therapeutic peptides, such as semaglutide and teriparatide, fall below 40 amino acids and are classified as drugs under the FDCA, not biologics.

What is a biosimilar vs a generic for a peptide?

If a peptide is a biologic (40+ amino acids, PHS Act Section 351), competitors seeking approval must file an Abbreviated BLA and demonstrate biosimilarity or interchangeability, not simple chemical identity. If the peptide is a drug (under FDCA Section 505), a generic can be approved via an ANDA showing pharmaceutical equivalence and bioequivalence, a much less burdensome standard.

Can compounding pharmacies compound peptides classified as biologics?

Compounding under Sections 503A and 503B of the FDCA applies to drug products, not biological products regulated under the PHS Act. Peptides classified as biologics cannot lawfully be compounded under the FDCA compounding exemptions. Peptides classified as drugs can be compounded, provided they are not on the FDA's Difficult to Compound list and other conditions are met.

How did the BPCIA 2009 change peptide regulation?

Before the BPCIA, proteins were ambiguously regulated under both statutes. The BPCIA clarified that proteins (amino acid polymers with a specific defined sequence, typically 40+ amino acids) are biologics under Section 351, and created the biosimilar approval pathway (351(k)). The transition provision took full effect March 23, 2020, after a 10-year implementation period.

Does the FDA regulate research-use peptides differently from approved drugs?

A peptide sold explicitly for human therapeutic use without FDA approval is an unapproved drug and subject to enforcement. Peptides sold for research use only (RUO) occupy a gray zone: the label protects the seller if the product is genuinely used for non-clinical research, but the FDA has taken enforcement action when RUO labeling is used as a fig leaf for human use distribution.

What does drug vs biologic status mean for market exclusivity?

Biologics approved under Section 351(a) receive 12 years of reference product exclusivity under the BPCIA, plus potential additional first-application exclusivity. New chemical entity drugs approved under Section 505(b)(1) receive 5 years of NCE exclusivity under the Hatch-Waxman Act. This makes the biologic pathway substantially more commercially protective for manufacturers.

What are examples of peptides regulated as drugs vs biologics?

Drug pathway: semaglutide (31 AA, NDA 209637), liraglutide (26 AA, NDA 022341), oxytocin (9 AA), teriparatide (34 AA, NDA 021318). Biologic pathway: insulin (51 AA across two chains, BLA post-2020), human growth hormone (191 AA, BLA), erythropoietin (BLA).

Why does the drug vs biologic distinction matter for peptide buyers?

It affects whether a generic or biosimilar version can enter the market and at what cost, whether a compounding pharmacy can legally prepare it, how long the innovator's exclusivity lasts, and what evidence standard the FDA requires for approval. Buyers of compounded peptides should verify the peptide's classification to assess legal and quality risk.

Is insulin now classified as a biologic?

Yes. As of March 23, 2020, insulin products previously approved as drugs under the FDCA were transitioned to biologic status under the BPCIA transition provision. Follow-on insulin products must now seek biosimilar approval under Section 351(k) rather than ANDA approval.

What does "analogous product" mean in the biologic definition?

The PHS Act phrase "analogous product" gives the FDA broad discretion to classify products as biologics even if they do not fit a named category. Courts and the FDA have interpreted this to cover products derived from living organisms with complex structures not fully definable by chemical synthesis. This keeps the biologic definition intentionally expansive.

Sources

1. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 321(g) (definition of drug). Available at: uscode.house.gov.
2. Public Health Service Act, 42 U.S.C. 262(i) (definition of biological product). Available at: uscode.house.gov.
3. Biologics Price Competition and Innovation Act of 2009, Public Law 111-148, Section 7002. Signed March 23, 2010. Available at: congress.gov.
4. FDA. Considerations for the Design, Development, and Analytical Procedures for Peptide Drug Products. Guidance for Industry. February 2018. Available at: fda.gov.
5. FDA. Drugs@FDA: FDA-Approved Drug Products. NDA 209637 (Ozempic, semaglutide). Available at: drugs.fda.gov.
6. FDA. Drugs@FDA: NDA 021318 (Forteo, teriparatide). Available at: drugs.fda.gov.
7. FDA. Drugs@FDA: NDA 022341 (Victoza, liraglutide). Available at: drugs.fda.gov.
8. FDA. Federal Register Vol. 85, No. 30, February 13, 2020. "List of Licensed Biological

   Related peptide guides

   • Peptide therapy guide hub
   • Peptide dosage and reconstitution calculator
   • Peptide vs Amino Acid: What's Actually Different | FormBlends
   • Peptide vs Amino Acid vs Protein: What Is the Real Difference? | FormBlends
   • A Hydrogen or Peptide Bond Binds Amino Acids Together: Which Is Correct? | FormBlends
   • Amide Bond vs Peptide Bond: Are They the Same Thing? | FormBlends
   • Amino Acids vs Peptides: What's the Real Difference? | FormBlends